BioDiem (ASX: BDM) is an ASX-listed company based in Melbourne with an international focus on discovering, developing and commercialising world-class research and technology targeting infectious diseases and related cancers. BioDiem’s core technologies include the Live Attenuated Influenza Virus (LAIV), the BDM-I antimicrobial compound and the SAVINE vaccine technology platform. BioDiem has also in-licensed vaccine technologies from Australian National University and the University of Canberra with initial target indications of dengue fever and hepatitis respectively.
View Top Employees from BioDiem Ltd| Website | http://www.biodiem.com |
| Revenue | $19 million |
| Employees | View employees |
| Address | 100 Albert Rd, Level 4, South Melbourne, Victoria 3205, AU |
| Phone | +61 3 9692 7222 |
| Fax | +61 3 9613 4111 |
| Industry | Chemicals, Petrochemicals, Glass & Gases, Biopharma, Manufacturing, Biotechnology, Health Care, Science and Engineering, Pharmaceutical |
| Competitors | Cel-Sci, ImmusanT, Inc., Meissa Vaccines, QuatRx Pharmaceuticals Company, T3D Therapeutics, Inc. |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 325414 Companies |
Looking for a particular BioDiem Ltd employee's phone or email?
BioDiem Ltd Questions
The BioDiem Ltd annual revenue was $19 million in 2024.
BioDiem Ltd is based in South Melbourne, Victoria.
The NAICS codes for BioDiem Ltd are [3254, 32, 32541, 325, 325414].
The SIC codes for BioDiem Ltd are [28, 283].
